Showing results (2191-2200 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|July 7, 2017
Availability and Pricing New Medicines in Ireland: Reflections and ReformPaul K GoreckiPharmacoeconomics|May 28, 2017
Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology AppraisalIñigo Bermejo, Matt Stevenson, Rachel Archer, et al.Pharmacoeconomics|May 5, 2018
Review of Economic Value Drivers of the Treatment of Overactive BladderSonya J SnedecorPharmacoeconomics|May 9, 2018
Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic EvaluationsR Brett McQueen, Danielle N Sheehan, Melanie D Whittington, et al.Pharmacoeconomics|May 11, 2018
Correction to: 3L, 5L, What the L? A NICE ConundrumNancy Devlin, John Brazier, A Simon Pickard, et al.Pharmacoeconomics|May 16, 2019
Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic ReviewStuart J Wright, William G Newman, Katherine PaynePharmacoeconomics|May 10, 2019
Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory DecisionsMutsa Gumbie, Bonny Parkinson, Henry Cutler, et al.Pharmacoeconomics|November 27, 2018
Future Costs in Cost-Effectiveness Analyses: Past, Present, FutureLinda M de Vries, Pieter H M van Baal, Werner B F BrouwerPharmacoeconomics|March 28, 2018
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology AppraisalXavier Armoiry, Martin Connock, Alexander Tsertsvadze, et al.Pharmacoeconomics|March 30, 2018
Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRachid Rafia, Abdullah Pandor, Sarah Davis, et al.Pageof 336